Tiziana Pia Latiano

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 325 citations · Full text

Medicine, Oncology, Pharmacotherapy +8

Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With <i>RAS</i> Wild-type Metastatic Colorectal Cancer

Erika Martinelli, Giulia Martini, Vincenzo Famiglietti et al. · JAMA Oncology · 2021 · 185 citations · Full text

Medicine, Oncology, Pharmacology +17

Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study

Daniele Santini, Marco Tampellini, Bruno Vincenzi et al. · Annals of Oncology · 2012 · 134 citations · Full text

Medicine, Oncology, Surgery +17

RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial

Nicola Normanno, Riziero Esposito Abate, Matilde Lambiase et al. · Annals of Oncology · 2017 · 119 citations

Medicine, Oncology, Pathology +17

Butyrate, a postbiotic of intestinal bacteria, affects pancreatic cancer and gemcitabine response in in vitro and in vivo models

Concetta Panebianco, Annacandida Villani, Federica Pisati et al. · Biomedicine & Pharmacotherapy · 2022 · 117 citations · Full text

Medicine, Oncology, Pharmacology +17